Meeting
2017 ASCO Annual Meeting
The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).
Authors
Daniel John Renouf
BC Cancer Agency, Vancouver, BC, Canada
Daniel John Renouf , Petr Kavan , Neesha C. Dhani , Derek J. Jonker , Alice Chia-chi Wei , Tina Hsu , Patricia A. Tang , Barbara Graham , Dongsheng Tu , Christopher J. O'Callaghan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02879318
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS4149)
DOI
10.1200/JCO.2017.35.15_suppl.TPS4149
Abstract #
TPS4149
Poster Bd #
132a
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Daniel John Renouf
Poster
2021 ASCO Annual Meeting
Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Gang Jin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai
Poster
2022 ASCO Annual Meeting
Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai